The Role of Checkpoint Inhibitors in Ovarian Cancer

In ovarian cancer, do you see any evidence in the high-grade series that there's correlation between benefit from checkpoint inhibitor and PD1 or anything else? And if we would identify a group of patients who are more apt to respond, I do believe over time, we may be able to differentiate. You know, I'm an optimist while at the same time, I'm a pessimist. But in this case, I do think there's something there. Maybe it's more hopeful than it is reality.